Resultado de búsqueda
9 de oct. de 2021 · Based on the best available evidence, we postulate a preferred treatment strategy for Stenotrophomonas maltophilia infection. The best scenario would be to reduce the likelihood of infection entirely through antibiotic stewardship and judicious antibiotic use, particularly of carbapenems, which have been consistently identified in ...
- Jean Gibb, Darren W. Wong
- 2021
13 de oct. de 2022 · Stenotrophomonas ( Xanthomonas) maltophilia is a multidrug-resistant gram-negative bacillus that is an opportunistic pathogen [ 1-4 ], particularly among hospitalized patients. S. maltophilia infections have been associated with high morbidity and mortality in severely immunocompromised and debilitated individuals.
12 de jun. de 2023 · The first-line treatment is trimethoprim-sulfamethoxazole, which has been the recommended empiric single agent against Stenotrophomonas maltophilia for many years.
- Mina S. Said, Ekta Tirthani, Emil Lesho
- 2023/06/12
In vitro trimetoprima-sulfametoxazol (TS) es el fármaco con mayor potencia frente a S. maltophilia, con tasas de sensibilidad generalmente superiores al 90% en estudios internacionales sobre resistencia antibiótica 9, aunque la resistencia al mismo es variable y puede alcanzar hasta el 25-58% 1.
- Juan E. Corzo-Delgado, Jesús M. Gómez-Mateos
- 2006
18 de ago. de 2020 · Trimethoprim/sulfamethoxazole (TMP/SMX) is considered the treatment of choice for S maltophilia infections based on reliable in vitro activity against clinical isolates and extensive clinical experience with its use. 4 However, due to adverse events associated with TMP/SMX as well as increasing prevalence of TMP/SMX resistance, alternative treat...
5 de may. de 2022 · Stenotrophomonas maltophilia is a non-fermenting, Gram-negative bacillus that has emerged as an opportunistic nosocomial pathogen. Its intrinsic multidrug resistance makes treating infections caused by S. maltophilia a great clinical challenge.
S. maltophilia may cause invasive infections of various tissues in hospitalized patients. In the great majority of cases it was susceptible to co-trimoxazole, levofloxacin and ceftazidime. In about three fourths of the cases, the treatment was successful, while less than 20% of the patients died.
